drugset / Trial / NCT02974660

Protamine Sulfate During Transcatheter Aortic Valve Implantation

NCT02974660

Phase 4 Completed 100 enrolled Medical University of Warsaw
RandomizedParallel-groupSingle-blindPrevention

Summary

Transcatheter aortic valve implantation (TAVI) is a new, rapidly emerging standard of care in inoperable and high-risk patients with severe, symptomatic aortic stenosis. Information regarding reversal of unfractionated heparin with protamine sulfate in order to facilitate access site closure is scarce and based on expert consensus. Clinical practice varies between centers. Protamine sulphate may decrease the amount of bleeding complications related to the access-site. The impact on possible thromboembolic complications is unknown. Both bleeding and thromboembolic complications increase mortality after TAVI. A randomized trial is required in order to assess impact of protamine sulfate on prevalence and extent of bleeding and thromboembolic complications.

Timeline

Start
2016-12
Primary completion
2020-07
Completion
2020-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Protamine Sulfate Unknown 1 mg Intravenous

Indications